Screening Gene Mutations in Chinese Patients With Benign Essential Blepharospasm

Hongjuan Dong, Ying Luo, Shanghua Fan, Bo Yin, Chao Weng and Bin Peng*

Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, China

Objective: This study aimed to screen gene mutations in Chinese patients with benign essential blepharospasm (BEB) to understand its etiology.

Methods: Twenty BEB patients diagnosed by clinical manifestations between April 2015 and October 2015 were enrolled. All the cases were investigated by questionnaires about general conditions, social behavioral factors, environmental factors, psychological factors, genetic factors, and previous diseases. In each patient, a total of 151 genes related to movement disorders were analyzed by second-generation sequencing.

Results: Two patients had a family history of BEB, and they had SYNE1 and Cdkn1A-interacting zinc finger protein 1 (CIZ1) mutation, respectively. We found the SYNE1 mutation in seven patients, the CIZ1 mutation in two patients, the CACNA1A mutation in two patients, the LRRK2 mutation in two patients, and the FUS mutation in two patients. The C10orf2, TPP1, SLC1A3, PNKD, EIF4G1, SE TX, PRRT2, SPTBN2, and TTBK2 mutations were found in only one patient, respectively, while not any mutation in the 151 genes were found in two patients. Some patients had mutations in two genes.

Conclusion: Genetic factors, especially SYNE1 and CIZ1 mutations, contribute to the etiology of BEB.

Keywords: benign essential blepharospasm, Chinese, gene mutation, SYNE1, CIZ1

INTRODUCTION

Blepharospasm is an adult-onset focal dystonia characterized by involuntary contraction of the orbicularis oculi muscles. Benign essential blepharospasm (BEB) is the most common form of blepharospasm, and its etiology remains elusive (1). Studies in various populations suggest that BEB has a prevalence of 12–133 cases per million (2). Most cases of BEB are considered sporadic; about 20–30% of cases have a family history. Epidemiological survey showed that BEB was more common in women than in men with a 2.3:1 ratio (3).

The average age of onset in blepharospasm patients is in the 50s, and the onset for the female is 4.7 years late compared with the male (4). Initially, the spasms are mild and infrequent, but symptoms typically progress and are highly disruptive to the patient's visual activities and quality of life (4). While some BEB patients have family history, the disease gene has not been determined. In familial BEB, DYT1, and other dystonia-related genes were detected, but no definitive pathogenic genes have been identified (5, 6). Therefore, in this study we aimed to screen gene mutations in Chinese BEB patients to understand its genetic etiology. We performed genetic testing in 20 BEB patients on 151 genes related to movement disorders, including 27 genes related to dystonia, 4 genes...
related to episodic ataxia (EA), 2 genes related to paroxysmal kinesigenic dyskinesia (PKD), 1 gene related to paroxysmal non-kinesigenic dyskinesia (PNKD), 3 genes related to essential tremor, 78 genes related to Parkinson’s disease, and PDK3, AFG3L2, and ANO10 (7, 8). We also analyzed the relationship between clinical manifestations and gene mutations in the 20 patients.

METHODS

Patients
This study was approved by the Medical Ethics Committee of Renmin Hospital of Wuhan University. Written informed consent was obtained from each patient. Twenty patients with BEB, who were referred to the Movement Disorders Clinic in the Department of Neurology at our hospital between April 2015 and October 2015, were evaluated through clinical examination and questionnaire. Each patient had neurological examination by a movement disorder specialist and completed a questionnaire. All patients had a full neurological examination to rule out other underlying neurological conditions.

The questionnaire was divided into four parts: general characteristics (onset time, age of onset, initial site, sensory tricks, first visit time, the time of confirmed diagnosis, blood pressure), past and family history (hypertension, diabetes, heart disease, hyperthyroidism, measles, cerebrovascular disease, brain trauma, encephalitis, ocular diseases), medicine history, and dangerous factors (pesticides, herbicides, preservatives, living environment, smoking and drinking, drug abuse).

Sequencing
Genomic DNA was extracted from the blood of each patient using Flexi DNA Kit (QIAGEN, Germany), which was sent to Kangso Medical Inspection (Beijing, China) for next-generation sequencing for genes listed in Table 1.

RESULTS

BEB was more common in women than in men. This study included 17 women and 3 men. The mean age was 55.25 years (range 31–72), and the mean duration of illness was 6.15 years (range 1–24). The early symptoms of the 20 patients were different. Nine patients had difficulty of opening the eyes, seven patients showed increased blinking, two patients were smokers. Three patients had a history of drinking. Five patients had a history of exposure to pesticides/herbicides.

A total of 15 patients chose to first consult an ophthalmologist. For the 151 genes we detected SYNE1 gene mutation in two cases, CACNA1A gene mutation in two cases, Cdkn1A-interacting zinc finger protein 1 (CIZ1) gene mutation in two cases, CACNA1A, KCNA1, SLC1A3, DARS2, ET 3 FUS, MAPT, LINGO1.

For treatment, all patients received botulinum toxin (BoNT). In most patients, the symptoms improved with BoNT but did not completely resolve. Seven patients received myectomy procedure. In addition, other treatments such as acupuncture were used but had no obvious benefits.

Two patients reported a family history of BEB. For the 151 genes listed in Table 1, we detected SYNE1 gene mutation in seven cases, Cdkn1A-interacting zinc finger protein 1 (CIZ1) gene mutation in two cases, CACNA1A gene mutation in two cases, CACNA1A gene mutation in two cases, CACNA1A gene mutation in two cases, FUS gene mutation in two cases, and C10orf2, TPPL1, SLC1A3, PNKD, EIF4G1, SETX, PRR2, SPTBN2, and TTBL2 gene mutation each in one case. Two patients did not have any mutations in the 151 genes. The clinical data and mutation genes of 20 patients with BEB are presented in Table 2. Representative CIZ1 and SYNE1 variants are shown in Figure 1.

DISCUSSION

The etiology of BEB is still unclear. It was speculated that the pathogenesis of BEB may be related to basal ganglia damage and the disorders of neurotransmitters such as dopamine (9–11).
The abnormality of dopaminergic pathways may be implicated in the pathogenesis of dystonia (11). In particular, BEB patients had reduced number of nerves in the sub-basal plexus, which suggested that the impairment in cortico sensory processing due to the defect of the sensorimotor gating mechanism could cause the loss of inhibition of blink reflex (12).

Genetic factors play an important role in neurological diseases (13). There is evidence for an autosomal-dominant gene with reduced penetrance contributing to BEB (14). Therefore, in this study we examined 151 genes in all BEB patients and found SYNE1 gene mutation in seven cases, CIZ1 gene mutation in two cases, CACNA1A gene mutation in two cases, LRRK2 gene mutation in two cases, FUS gene mutation in two cases, and C10orf2, TPP1, SLC1A3, PNKD, EIF4G1, SETX, PRRT2, SPTBN2, and TTBK2 gene mutation in each case. Interestingly, a recent study showed that deleterious variants in CACNA1A, REEP4, TOR2A, ATP2A3, HS1BP3, GNA14, and DNAH17 were involved in blepharospasm, and none of these variants except for CACNA1A has been reported to be associated with blepharospasm (15). However, a follow-up study reported that all variants detected in GNAL, CIZ1, and TOR2A seemed to be benign in 132 blepharospasm patients (16). Therefore, we should investigate the status of these variants in our patients in further studies.

SYNE1 gene encodes nesprin-1 protein and genome-wide association studies have revealed the strong association of SYNE1 gene with bipolar disorder and major depression (17). In particular, a recent study showed that genetic variation in the CPG2 region of SYNE1 could be linked to glutamatergic synapse dysfunction and the susceptibility to bipolar disorder (18). While BEB is commonly associated with emotional disorders, to our knowledge, no direct association between SYNE1 and BEB has been reported in the literatures. In this study, we found the highest number of patients that had gene mutations in SYNE1 gene, suggesting that SYNE1 may play a role in the pathogenesis of BEB. CIZ1 was first identified as a protein that interacted with CDK2 inhibitor p21. CIZ1 gene localizes on 9q34, and the encoded protein CIZ1 is comprised of 842 amino acid residues with CDK2 inhibitor p21. CIZ1 gene localizes on 9q34, and the encoded protein CIZ1 is comprised of 842 amino acid residues and contains two glutamine-rich domains, three C2H2-type zinc finger motifs, an acidic domain, and an MH3 domain. CIZ1 was first identified as a protein that interacted with CDK2 inhibitor p21. CIZ1 gene localizes on 9q34, and the encoded protein CIZ1 is comprised of 842 amino acid residues and contains two glutamine-rich domains, three C2H2-type zinc finger motifs, an acidic domain, and an MH3 domain.

### Table 2: Clinical data and mutation genes of 20 patients with BEB.

| Patient number | Gender | Age (years) | Family history | Duration (years) | Mutation genes | Heterozygous variant |
|----------------|--------|-------------|----------------|------------------|----------------|---------------------|
| 1              | F      | 55          | N              | 6                | PARK2          | c.652T>A            | p.Ser218Thr          |
| 2              | F      | 44          | N              | 3                | SETX           | c.389-9delT         |                     |
| 3              | F      | 63          | N              | 1                | SPTBN2         | c.5939C>A           | p.Ala1898Glu         |
| 4              | F      | 52          | N              | 8                | SYNE1          | c.776A>G            | p.Asn259Ser          |
| 5              | F      | 65          | N              | 8                | SYNE1          | c.5438A>G           | p.His1813Arg         |
| 6              | F      | 52          | N              | 10               | CIZ1           | c.17438C>G          | p.Pro5813Arg         |
| 7              | F      | 46          | N              | 4                | CIZ1           | c.17438C>G          | p.Pro5813Arg         |
| 8              | F      | 47          | Y              | 4                | SYNE1          | c.13072G>A          | p.Arg8000His         |
| 9              | M      | 31          | N              | 1                | SYNE1          | c.13072G>A          | p.Arg8000His         |
| 10             | M      | 52          | N              | 4                | SYNE1          | c.13072G>A          | p.Arg8000His         |
| 11             | F      | 62          | N              | 6                | LRRK2          | c.4443G>A           | p.Val1210Le          |
| 12             | F      | 63          | N              | 2                | LRRK2          | c.5078G>A           | p.Arg1693Gln         |
| 13             | M      | 57          | N              | 2                | C10orf2        | c.1495G>T           | p.Arg499Ty           |
| 14             | F      | 70          | Y              | 10               | CIZ1           | c.1968C>G           | p.Pro134Ser          |
| 15             | F      | 52          | N              | 1                | PNKD           | c.301C>T            | p.Arg101Trp          |
| 16             | F      | 72          | N              | 24               | SLC1A3         | c.985G>A            | p.Ala292Thr          |
| 17             | F      | 52          | N              | 5                | TPP1           | c.1681C>T           | p.Leu661Phe          |
| 18             | F      | 52          | N              | 12               | TTBK2          | c.3290T>C           | p.Val1097Ala         |
| 19             | F      | 59          | N              | 6                | -              | -                   |                     |
| 20             | F      | 59          | N              | 6                | -              | -                   |                     |
number of patients is small. Secondly, several potential new genes associated with BEB have been reported recently, and they were not included in the genes that we screened in our study. Further studies are needed to understand the pathogenic mechanism of BEB in Chinese patients.

DATA AVAILABILITY STATEMENT

All datasets generated for this study are included in the article/supplementary material.

ETHICS STATEMENT

This study was approved by Medical Ethics Committee of Renmin Hospital of Wuhan University. Written informed consent was obtained from each patient. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

BP contributed to the design of the study. HD and YL contributed to manuscript drafting. SF and BY in collected and analyzed the samples. CW helped to analysis the data and draw the figure and revised the paper. All authors finally approved the version to be published and agree to be accountable for all aspects of the work.

FUNDING

This study was supported by Hubei Provincial Natural Science Foundation of China (Grant No. ZRMS2018000870).

REFERENCES

1. Hwang CJ, Eftekhar K. Benign essential blepharospasm: what we know and what we don’t. Int Ophthalmol Clin. (2018) 58:11–24. doi: 10.1097/IIO.000000000000207
2. Yen MT. Developments in the treatment of benign essential blepharospasm. Curr Opin Ophthalmol. (2018) 29:440–4. doi: 10.1097/ICO.0000000000000500
3. Dong H, Fan S, Luo Y, Peng B. Botulinum toxin relieves anxiety and depression in patients with hemifacial spasm and blepharospasm. Neuropsychiatr Dis Treat. (2018) 15:33–6. doi: 10.2147/NDT.S181820
4. Defazio G, Hallett M, Jinnah HA, Conte A, Berardelli A. Blepharospasm 40 years later. Mov Disord. (2017) 32:498–509. doi: 10.1002/mds.26934
5. Peterson DA, Sejnowski TJ. A dynamic circuit hypothesis for the pathogenesis of blepharospasm. Front Comput Neurosci. (2017) 11:11. doi: 10.3389/fncom.2017.00011
6. Defazio G, Matarin M, Peckham EL, Martino D, Valente EM, Singleton A, et al. The TOR1A polymorphism rs1182 and the risk of spread in primary blepharospasm. Mov Disord. (2009) 24:613–6. doi: 10.1002/mds.22471

7. Graziola F, Garone G, Streapede F, Bosco L, Vigevano F, Curatolo P, et al. Diagnostic yield of a targeted next-generation sequencing gene panel for pediatric-onset movement disorders: a 3-year cohort study. Front Genet. (2019) 10:1026 doi: 10.3389/fgene.2019.01026

8. Krebs CE, Paisán-Ruiz C. The use of next-generation sequencing in movement disorders. Front Gene. (2012) 3:75. doi: 10.3389/fgene.2012.00075

9. Defazio G, Conte A, Gigante AF, Ferrazzano G, Pellicciari R, D’Agostino S, et al. Clinical heterogeneity in patients with idiopathic blepharospasm: a cluster analysis. Parkinsonism Relat Disord. (2017) 40:64–8. doi: 10.1016/j.parkreldis.2017.04.014

10. Evinger C. Benign essential blepharospasm is a disorder of neuroplasticity: lessons from animal models. J Neuroophthalmol. (2015) 35:374–9. doi: 10.1097/WNO.0000000000000317

11. Karimi M, Moerlein SM, Videen TO, Luedtke RR, Taylor M, Mach RH, et al. Decreased striatal dopamine receptor binding in primary focal dystonia: a D2 or D3 defect? Mov Disord. (2011) 26:100–6. doi: 10.1002/mds.23401

12. Fayers T, Shaw SR, Hau SC, Ezra DG. Changes in corneal aesthesiometry and the sub-basal nerve plexus in benign essential blepharospasm. Br J Ophthalmol. (2015) 99:1509–13. doi: 10.1136/bjophthalmol-2014-306426

13. Cong L, Kong X, Wang J, Du J, Xu Z, Xu Y, et al. Association between SORL1 polymorphisms and the risk of Alzheimer’s disease. J Integr Neurosci. (2018) 17:185–92. doi: 10.3233/JIN-170051

14. Xiromerisiou G, Dardiotis E, Tsironi EE, Hadjigeorgiou G, Ralli S, Kara E, et al. THAP1 mutations in a Greek primary blepharospasm series. Parkinsonism Relat Disord. (2013) 19:404–5. doi: 10.1016/j.parkreldis.2012.08.015

15. Tian J, Vemula SR, Xiao J, Valente EM, Defazio G, Petrucci S, et al. Whole-exome sequencing for variant discovery in blepharospasm. Mol Genet Genomic Med. (2018) 16:601–26. doi: 10.1002/mg3.411

16. Hammer M, Abravanel A, Peckham E, Mahloogi A, Majounie E, Hallett M, et al. Blepharospasm: a genetic screening study in 132 patients. Parkinsonism Relat Disord. (2019) 64:315–8. doi: 10.1016/j.parkreldis.2019.04.003

17. Green EK, Grozeva D, Forty L, Gordon-Smith K, Russell E, Farmer A, et al. Association at SYNE1 in both bipolar disorder and recurrent major depression. Mol Psychiatry. (2013) 18:614–7. doi: 10.1038/mp.2012.48

18. Rathje M, Waxman H, Benoit M, Tammineni P, Leu C, Loebrich S, et al. Genetic variants in the bipolar disorder risk locus SYNE1 that affect CPG2 expression and protein function. Mol Psychiatry. (2019). doi: 10.1038/s41380-018-0314-z. [Epub ahead of print].

19. Copeland NA, Sercombe HE, Ainscough JF, Coverley D. Ciz1 cooperates with cyclin-A-CDK2 to activate mammalian DNA replication in vitro. J Cell Sci. (2010) 12:1108–1115. doi: 10.1242/jcs.059345

20. Xiao J, Uitti RJ, Zhao Y, Vemula SR, Perlmutter JS, Wszolek ZK, et al. Mutations in CIZ1 cause adult onset primary cervical dystonia. Ann Neurol. (2012) 71:458–69. doi: 10.1002/ana.23547

21. Balint B, Bhattacharyya NP. Isolated and combined dystonia syndromes—an update on new genes and their phenotypes. Eur J Neurol. (2015) 22:610–7. doi: 10.1111/ene.12650

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Dong, Luo, Fan, Yin, Weng and Peng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.